The “Translational Biomarkers of Aging and Dementia” (TRIAD) project, led by Dr. Pedro Rosa-Neto, aims to develop a blood test capable of detecting Alzheimer’s disease before the onset of symptoms. This test, which could replace costly and invasive diagnostic methods such as brain imaging and lumbar puncture, seeks to identify amyloid plaques and the tau protein present in the blood. If validated, this test could revolutionize the early diagnosis of dementia, offering the possibility of intervening before clinical symptoms develop. Dr Rosa-Neto anticipates a “paradigm shift” in the field, potentially achievable within one or two years, thanks to technological advances supported by the Fonds de recherche du Québec.